BioHarvest takes second plant-cell asset to commercial readinessProactive Investors · Oct 13, 2026
BioHarvest Advances Proprietary Olive Cell Asset to Commercial Readiness, Opening New CDMO Licensing OpportunityNewsfile Corp · Oct 13, 2026
BioHarvest says its platform can produce target sweetener in Tate & Lyle programProactive Investors · Oct 8, 2026
Tate & Lyle and Bioharvest Reach Key Milestone in Next-Generation Sweetener Development ProgrammeNewsfile Corp · Oct 8, 2026
BioHarvest Sciences launches buyback of up to 5% of sharesProactive Investors · Sep 29, 2026
BioHarvest Sciences Announces Share Repurchase ProgramNewsfile Corp · Sep 29, 2026BioHarvest Sciences Inc. is a biotechnology company that operates through two segments: Products and CDMO Services. The company has developed a botanical synthesis platform technology to grow plant cells with higher concentrations of active ingredients. It is involved in the research, development, manufacturing, and sale of science-based health and wellness nutraceutical solutions, as well as offering Contract Development and Manufacturing Operation (CDMO) services to third parties in the pharmaceutical, cosmeceutical, and nutrition industries.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 11, 2026 | -$0.13 | -$0.17 | Miss |
| May 14, 2026 | -$0.13 | -$0.11 | Beat |
| Mar 31, 2026 | -$0.11 | -$0.10 | Beat |
| Nov 13, 2025 | -$0.14 | -$0.14 | Beat |
| Aug 11, 2025 | -$0.11 | -$0.24 | Miss |
| May 15, 2025 | -$0.15 | -$0.13 | Beat |